Hologic is a medical instruments & supplies business based in the US. Hologic shares (HOLX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $78.72 – an increase of 0.15% over the previous week. Hologic employs 6,990 staff and has a trailing 12-month revenue of around $4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $78.72 |
|---|---|
| 52-week range | $67.59 - $84.67 |
| 50-day moving average | $80.77 |
| 200-day moving average | $77.48 |
| Wall St. target price | $87.22 |
| PE ratio | 23.8585 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $3.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $78.04 from 2024-11-20
| 1 week (2024-11-14) | 0.64% |
|---|---|
| 1 month (2024-10-21) | -3.83% |
| 3 months (2024-08-21) | -2.47% |
| 6 months (2024-05-21) | 4.68% |
| 1 year (2023-11-21) | 8.52% |
|---|---|
| 2 years (2022-11-21) | 6.09% |
| 3 years (2021-11-19) | 3.60% |
| 5 years (2019-11-21) | 57.66% |
Valuing Hologic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hologic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hologic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Hologic shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hologic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2762. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hologic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hologic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.2 billion.
The EBITDA is a measure of a Hologic's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 24.36% |
| Gross profit TTM | $2.5 billion |
| Return on assets TTM | 6.45% |
| Return on equity TTM | 13.85% |
| Profit margin | 17.59% |
| Book value | $21.34 |
| Market Capitalization | $18 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hologic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hologic's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 58th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Hologic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.95/100
Hologic's environmental score of 2.95 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 11.28/100
Hologic's social score of 11.28 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Hologic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.88/100
Hologic's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Hologic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Hologic scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Hologic has, for the most part, managed to keep its nose clean.
Hologic Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.6 |
|---|---|
| Total ESG percentile | 58.02 |
| Environmental score | 2.95 |
| Environmental score percentile | 1 |
| Social score | 11.28 |
| Social score percentile | 1 |
| Governance score | 8.88 |
| Governance score percentile | 1 |
| Level of controversy | 2 |
We're not expecting Hologic to pay a dividend over the next 12 months.
Hologic's shares were split on a 2:1 basis on 2 April 2008 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Hologic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Hologic shares which in turn could have impacted Hologic's share price.
Over the last 12 months, Hologic's shares have ranged in value from as little as $67.5921 up to $84.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hologic's is 0.986. This would suggest that Hologic's shares are less volatile than average (for this exchange).
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.